

呼吸器・アレルギー内科グループ 英語論文の業績 2021年

- 1) Nishiyama H, Tajiri T, Yamabe T, Yasukawa T, Takeda N, Fukumitsu K, Fukuda S, Kanemitsu Y, Uemura T, Ohkubo H, Takemura M, Maeno K, Ito Y, Oguri T, Naniwa T, Niimi A. **Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody.** Intern Med. **60(22)**:3631-3634, 2021.
- 2) Tajiri T, Kawachi H, Yoshida H, Noguchi S, Terashita S, Ikeue T, Horikawa S, Sugita T, Niimi A. **The causes of acute cough: a tertiary-care hospital study in Japan.** J Asthma. **58(11)**:1495-1501, 2021.
- 3) Lee JH, Kang SY, Yoo Y, An J, Park SY, Lee SE, Kim MH, Kanemitsu Y, Chang YS, Song WJ. **Epidemiology of adult chronic cough: disease burden, regional issues, and recent findings.** Asia Pac Allergy; **11**: e38. 2021.
- 4) Ohkubo H, Nakano A, Fujita K, Ozawa Y, Murase T, Niimi A. **Spontaneous improvement of interstitial pneumonia with autoimmune features: A case report.** Respirol Case Rep. **9(11)**:e0867, 2021.
- 5) Kurokawa R, Kanemitsu Y, Fukumitsu K, Takeda N, Yap JM, Suzuki M, Mori Y, Fukuda S, Uemura T, Tajiri T, Ohkubo H, Maeno K, Ito Y, Oguri T, Takemura M, Niimi A. **The diagnostic utility of the frequency scale for the symptoms of gastroesophageal reflux disease questionnaire (FSSG) for patients with subacute/chronic cough.** J Asthma. **58(11)**:1502-1511, 2021.
- 6) Song WJ, Niimi A. **Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch.** J Allergy Clin Immunol Pract. **9(9)**:3440-3441, 2021.
- 7) Lee JH, Lee JW, An J, Won HK, Park SY, Kang SY, Kanemitsu Y, Kim HJ, Song WJ. **Efficacy of non-sedating H1-receptor antihistamines in adults and adolescents with chronic cough: A systematic review.** World Allergy Organ J; **14**: 100568. 2021.
- 8) Morimoto C, Matsumoto H, Tajiri T, Gon Y, Ito R, Hashimoto S, Suzukawa M, Ohta K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Kanemitsu Y, Nagasaki T, Izuhara Y, Niimi A, Hirai T. **High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study.** J Asthma. **58(9)**:1133-1142, 2021.
- 9) Uemura T, Fukumitsu K, Maeno K, Fukuda S, Onuki T, Kanemitsu Y, Oguri T, Niimi A, Hida T. **Asthma caused by durvalumab after chemoradiotherapy in two patients with non-small cell lung cancer.** Respirol Case Rep. **9(9)**:e0835, 2021.
- 10) Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. **Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.** J Thorac Oncol. **16(9)**:1523-1532, 2021.
- 11) Hori Y, Fukumitsu K, Naitoh I, Onuki T, Hayashi K, Niimi A, Kataoka H. **Endoscopic ultrasound-guided transesophageal drainage for acute mediastinitis caused by pancreatic fistula.** Respir Med Case Rep. **28**:34:101480, 2021.
- 12) Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y, Yoshioka H, Yamanaka T, Goto K. **Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).** Transl Lung Cancer Res. **10(7)**:3059-3070, 2021.

- 13) Niimi A. **Natural Language Processing: A Promising Research Tool of Chronic Cough for the Big Data Era.** *Chest.* **159(6):**2149-2150, 2021.
- 14) Kishimoto Y, Shirai T, Akamatsu T, Suzuki T, Asada K, Kanemitsu Y, Niimi A. **Validation of the Japanese version of the Manchester Cough in Lung Cancer Scale.** *Respir Investig.* **59(6):**865-870, 2021.
- 15) Niimi A. **Redefining "one airway, one disease": Broader classification considering specific pathophysiology and treatment.** *Respir Investig.* **59(5):**573-575, 2021.
- 16) Niimi A. **Narrative Review: how long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated?** *J Thorac Dis.* **13(5):**3197-3214, 2021.
- 17) Miura Y, Ohkubo H, Niimi A, Kanazawa S. **Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model.** *ERJ Open Res.* **7(4):**00345-2021, 2021.
- 18) Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K, Terada J, Niimi A, Matsuse H, Yatera K, Yamamoto Y, Azuma A, Arakawa H, Iwanaga T, Ogawa H, Kurahashi K, Gon Y, Sakamoto H, Shibata Y, Tamada T, Nishioka Y, Haranaga S, Fujieda S, Miyashita N, Mochizuki H, Yokoyama A, Yoshihara S, Tamaoki J. **JRS guidelines committee for the management of cough and sputum. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition).** *Respir Investig.* **59(3):**270-290, 2021.
- 19) Abdulqawi R, Satia I, Kanemitsu Y, Khalid S, Holt K, Dockry R, Woodcock AA, Smith JA. **A Randomized Controlled Trial to Assess the Effect of Lidocaine Administered via Throat Spray and Nebulization in Patients with Refractory Chronic Cough.** *J Allergy Clin Immunol Pract;* **9:** 1640-1647. 2021
- 20) Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N. **Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.** *Eur J Cancer.* **145:**183-193, 2021.
- 21) Sunadome H, Matsumoto H, Tohda Y, Horiguchi T, Kita H, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Iwanaga T, Hozawa S, Niimi A, Kanemitsu Y, Nagasaki T, Tashima N, Ishiyama Y, Morimoto C, Oguma T, Tajiri T, Ito I, Ono J, Ohta S, Izuhara K, Hirai T. **Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort.** *Allergol Int.* **70(2):**252-254, 2021.
- 22) Niimi A. **PATHOPHYSIOLOGY AND NOVEL TREATMENT STRATEGY OF REFRACTORY/UNEXPLAINED CHRONIC COUGH.** *Arerugi.* **70(2):**112-117, 2021.
- 23) Tajiri T, Matsumoto H, Jinnai M, Kanemitsu Y, Nagasaki T, Iwata T, Inoue H, Nakaji H, Oguma T, Ito I, Niimi A. **Pathophysiological relevance of sputum MUC5AC and MUC5B levels in patients with mild asthma.** *Allergol Int.* **71(2):**193-199, 2021.
- 24) Omote N, Kanemitsu Y, Inoue T, Yonezawa T, Ichihashi T, Shindo Y, Sakamoto K, Ando A, Suzuki A, Niimi A, Ito S, Imaizumi K, Hashimoto N. **Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19.** *Intern Med.* **61(2):**233-236, 2021.

- 25) Morimoto C, Matsumoto H, Nagasaki T, Kanemitsu Y, Ishiyama Y, Sunadome H, Oguma T, Ito I, Murase K, Kawaguchi T, Tabara Y, Niimi A, Muro S, Matsuda F, Chin K, Hirai T. **Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study.** *Respir Res.* **22(1):6**, 2021.
- 26) Yap JMG, Ueda T, Kanemitsu Y, Takeda N, Fukumitsu K, Fukuda S, Uemura T, Tajiri T, Ohkubo H, Maeno K, Ito Y, Oguri T, Ugawa S, Niimi A. **AITC inhibits fibroblast-myofibroblast transition via TRPA1-independent MAPK and NRF2/HO-1 pathways and reverses corticosteroids insensitivity in human lung fibroblasts.** *Respir Res.* **22(1):51**, 2021.
- 27) Oya Y, Yoshida T, Asada K, Oguri T, Inui N, Morikawa S, Ito K, Kimura T, Kunii E, Matsui T, Kubo A, Kato T, Abe T, Tsuda T, Hida T. **Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.** *BMC Cancer.* **21(1):57**, 2021.